Business Context and Reporting Period
This Form 8-K was filed by BioRestorative Therapies, Inc. on April 10, 2012, reporting events occurring on April 10 and April 11, 2012. The filing serves to disclose two significant corporate developments: the completion of a private financing round and the effective date of a strategic license agreement.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, or debt levels. The only specific financial metric disclosed is the amount of capital raised:
- Private Financing: $2,100,000 obtained during 2012.
Liquidity, debt, and other operational metrics are not detailed in this specific report.
Material Changes
The filing highlights two material events:
- Capital Raise: The Company secured $2.1 million in private financing in 2012.
- Strategic Partnership: A License Agreement with Regenerative Sciences, LLC became effective on April 11, 2012.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future performance, or specific risk factors beyond the standard disclaimer. The Company explicitly states that the information in the associated press releases is being furnished, not filed, and does not constitute a determination that the information is material or complete for investment decision-making purposes.
Investor Verification Checklist
- Verify the terms and conditions of the $2.1 million private financing (e.g., interest rate, equity conversion, maturity).
- Review the specific scope and financial terms of the License Agreement with Regenerative Sciences, LLC.
- Confirm the Company's current cash position and runway following the financing.
- Check for any subsequent filings regarding the utilization of the raised capital.